Longevity Research

{
  "result": " This tick, the swarm concentrated its scanning and hypothesis-generation capacity on a single, high-priority causal edge: whether mTORC1 inhibition—through genetic perturbation of *RPTOR* and *AKT1S1* or pharmacological mimicry with everolimus—can suppress systemic inflammaging markers (IL-6 and hs-CRP) via autophagy-dependent mechanisms in human macrophages. The planned convergent approach combines rare protein-truncating variant drug-target Mendelian randomization (MR) in UK Biobank and FinnGen, multivariable MR adjusting for LDL-C and BMI to control metabolic pleiotropy, orthogonal iPSC-derived macrophage CRISPRi experiments, and trans-ethnic fine-mapping across European, East Asian, and African ancestry cohorts. Despite updating three hypotheses and cataloguing 142 entities, the swarm produced zero new empirical relations this cycle; the knowledge base remains at 0 traversable edges, underscoring that this phase was strictly dedicated to instrument design and literature scaffolding.\n\nThe biological mechanism under investigation posits mTORC1 as a central nutrient sensor that, when dampened, may activate cellular recycling (autophagy) and thereby quiet inflammatory signaling. In the proposed iPSC-macrophage model, *RPTOR* knockdown or everolimus exposure would trigger nuclear translocation of TFEB and TFE3—transcription factors that act as master regulators of lysosomal and autophagy genes—while accelerating SQSTM1/p62 flux, a readout of active protein clearance. The downstream hypothesis is that this autophagic surge reduces phosphorylation of NF-κB p65 at Ser536, a key activation mark for the inflammation master regulator NF-κB, ultimately lowering secretion of IL-6 and high-sensitivity CRP. The critical question is whether this anti-inflammatory effect is autophagy-dependent; the swarm plans to test this by dual *RPTOR* and *ATG7* CRISPRi, which would disable the autophagy machinery and reveal if the pathway is required for the phenotype.\n\nEvidence strength for the specific mTORC1–autophagy–IL-6/CRP relation remains at the hypothesis level. This tick yielded no new human genetic associations, no in vitro macrophage perturbation data, and no cross-ancestry validation. While the broader longevity literature provides substantial in vivo animal evidence that mTOR inhibition extends healthspan and some human observational data linking rapamycin analogs to immune modulation, those findings do not confirm that the specific anti-inflammatory effect in human macrophages operates through the autophagy–NF-κB axis proposed here. Until the planned MR and cellular assays are executed, the evidentiary basis for this edge is conceptual rather than empirical.\n\nFor the next tick, the swarm must answer whether rare variants in *RPTOR* and *AKT1S1* exhibit causal, directionally consistent effects on IL-6 and hs-CRP independent of lipid and adiposity confounders; whether *RPTOR* knockdown in human iPSC-macrophages authentically suppresses NF-κB signaling and whether that suppression collapses when *ATG7* is co-disrupted; and whether the 17q25.3 signals are portable across ancestries and colocalize with macrophage expression quantitative trait loci. Broader cytokine panels, clinical trial trajectories such as PEARL/EXIST, and parallel mTORC2/*RICTOR* tracks remain deprioritized until this first edge is populated. Directionally, the mTOR–autophagy–inflammation axis is a compelling theoretical bridge between nutrient sensing and immune aging, but confidence in this specific traversable pathway remains low pending experimental execution.\n\nThese findings are generated by an AI scanning published literature and should not be interpreted as medical advice.",
  "items_processed": 60,
  "findings": 0,
  "hypotheses": 3
}